Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

RET Fusion Testing in Patients With NSCLC, The RETING Study

  • Conde, Esther
  • Hernandez, Susana
  • Rodriguez Carrillo, Jose Luis
  • Martinez, Rebeca
  • Alonso, Marta
  • Curto, Daniel
  • Jimenez, Beatriz
  • Caminoa, Alejandra
  • Benito, Amparo
  • Garrido, Pilar|||0000-0002-5899-6125
  • Clavé, Sergi|||0000-0002-9435-8454
  • Arriola, Edurne|||0000-0001-8960-7519
  • Esteban Rodríguez, Isabel|||0000-0003-1576-7215
  • Castro, Javier de|||0000-0002-3622-6306
  • Sansano, Irene|||0000-0003-0188-5210
  • Felip, Enriqueta|||0000-0002-7620-0098
  • Rojo, Federico|||0000-0001-9989-0290
  • Dómine Gómez, Manuel|||0000-0003-1634-9832
  • Abdulkader, Ihab
  • Garcia-Gonzalez, Jorge
  • Teixidó, Cristina|||0000-0002-7226-6567
  • Reguart, Noemi|||0000-0001-8190-499X
  • Compañ, Desamparados
  • Insa, Amelia|||0000-0002-3438-6170
  • Mancheño, Nuria
  • Palanca, Sarai
  • Juan, Óscar|||0000-0002-7772-9030
  • Baixeras, Nuria|||0000-0001-6127-0475
  • Nadal, Ernest|||0000-0002-9674-5554
  • Cebollero, Maria
  • Calles, Antonio
  • Martin, Paloma
  • Salas, Clara
  • Provencio Pulla, Mariano|||0000-0001-6315-7919
  • Aranda, Ignacio
  • Massuti, Bartomeu|||0000-0002-6247-4493
  • López Vilaró, Laura|||0000-0002-5428-8017
  • Majem Tarruella, Margarita|||0000-0002-9919-7485
  • Paz-Ares, Luis|||0000-0002-3327-3246
  • Lopez-Rios, Fernando
RET inhibitors with impressive overall response rates are now available for patients with NSCLC, yet the identification of RET fusions remains a difficult challenge. Most guidelines encourage the upfront use of next-generation sequencing (NGS), or alternatively, fluorescence in situ hybridization (FISH) or reverse transcriptase-polymerase chain reaction (RT-PCR) when NGS is not possible or available. Taken together, the suboptimal performance of single-analyte assays to detect RET fusions, although consistent with the notion of encouraging universal NGS, is currently widening some of the clinical practice gaps in the implementation of predictive biomarkers in patients with advanced NSCLC. This situation prompted us to evaluate several RET assays in a large multicenter cohort of RET fusion-positive NSCLC (n = 38) to obtain real-world data. In addition to RNA-based NGS (the criterion standard method), all positive specimens underwent break-apart RET FISH with two different assays and were also tested by an RT-PCR assay. The most common RET partners were KIF5B (78.9%), followed by CCDC6 (15.8%). The two RET NGS-positive but FISH-negative samples contained a KIF5B(15)-RET(12) fusion. The three RET fusions not identified with RT-PCR were AKAP13(35)-RET(12), KIF5B(24)-RET(9) and KIF5B(24)-RET(11). All three false-negative RT-PCR cases were FISH-positive, exhibited a typical break-apart pattern, and contained a very high number of positive tumor cells with both FISH assays. Signet ring cells, psammoma bodies, and pleomorphic features were frequently observed (in 34.2%, 39.5%, and 39.5% of tumors, respectively). In-depth knowledge of the advantages and disadvantages of the different RET testing methodologies could help clinical and molecular tumor boards implement and maintain sensible algorithms for the rapid and effective detection of RET fusions in patients with NSCLC. The likelihood of RET false-negative results with both FISH and RT-PCR reinforces the need for upfront NGS in patients with NSCLC.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

  • Conde, E.
  • Hernandez, S.
  • Martinez, R.
  • Angulo, B.
  • De Castro, J.
  • Collazo-Lorduy, A.
  • Jimenez, B.
  • Muriel, A.
  • Mate, J.L.
  • Moran, T.
  • Aranda, I.
  • Massuti, B.
  • Rojo, F.
  • Domine, M.
  • Sansano, I.
  • Garcia, F.
  • Felip, E.
  • Mancheño, N.
  • Juan, O.
  • Sanz, J.
  • Gonzalez-Larriba, J.L.
  • Atienza-Cuevas, L.
  • Arriola-Arellano, E.
  • Abdulkader, I.
  • Garcia-Gonzalez, J.
  • Camacho, C.
  • Rodriguez-Abreu, D.
  • Teixido, C.
  • Reguart, N.
  • Gonzalez-Piñeiro, A.
  • Lazaro-Quintela, M.
  • Lozano, M.D.
  • Gurpide, A.
  • Gomez-Roman, J.
  • Lopez-Brea, M.
  • Pijuan, L.
  • Salido, M.
  • Arriola, E.
  • Company, A.
  • Insa, A.
  • Esteban-Rodriguez, I.
  • Saiz, M.
  • Azkona, E.
  • Alvarez, R.
  • Artal, A.
  • Plaza, M.L.
  • Aguiar, D.
  • Enguita, A.B.
  • Benito, A.
  • Paz-Ares, L.
  • Garrido, P.
  • Lopez-Rios, F.
Introduction: The ROS1 gene rearrangement has become an important biomarker in NSCLC. The College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology testing guidelines support the use of ROS1 immunohistochemistry (IHC) as a screening test, followed by confirmation with fluorescence in situ hybridization (FISH) or a molecular test in all positive results. We have evaluated a novel anti-ROS1 IHC antibody (SP384) in a large multicenter series to obtain real-world data. Methods: A total of 43 ROS1 FISH–positive and 193 ROS1 FISH–negative NSCLC samples were studied. All specimens were screened by using two antibodies (clone D4D6 from Cell Signaling Technology and clone SP384 from Ventana Medical Systems), and the different interpretation criteria were compared with break-apart FISH (Vysis). FISH-positive samples were also analyzed with next-generation sequencing (Oncomine Dx Target Test Panel, Thermo Fisher Scientific). Results: An H-score of 150 or higher or the presence of at least 70% of tumor cells with an intensity of staining of 2+ or higher by the SP384 clone was the optimal cutoff value (both with 93% sensitivity and 100% specificity). The D4D6 clone showed similar results, with an H-score of at least 100 (91% sensitivity and 100% specificity). ROS1 expression in normal lung was more frequent with use of the SP384 clone (p < 0.0001). The ezrin gene (EZR)-ROS1 variant was associated with membranous staining and an isolated green signal FISH pattern (p = 0.001 and p = 0.017, respectively). Conclusions: The new SP384 ROS1 IHC clone showed excellent sensitivity without compromising specificity, so it is another excellent analytical option for the proposed testing algorithm.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma, the ROSING Study

  • Conde, Esther
  • Hernández, Susana
  • Martinez, Rebeca
  • Angulo, Bárbara
  • Castro, Javier de|||0000-0002-3622-6306
  • Collazo-Lorduy, Ana
  • Jiménez-Munarriz, Beatriz Carolina
  • Muriel, Alfonso|||0000-0002-4805-4011
  • Mate Sanz, Jose Luís|||0000-0002-4829-3426
  • Morán, Teresa
  • Aranda, Ignacio
  • Massuti, Bartomeu|||0000-0002-6247-4493
  • Rojo, Federico|||0000-0001-9989-0290
  • Dómine Gómez, Manuel|||0000-0003-1634-9832
  • Sansano, Irene|||0000-0003-0188-5210
  • Garcia, Felip
  • Felip, Enriqueta|||0000-0002-7620-0098
  • Mancheño, Nuria
  • Juan, Óscar|||0000-0002-7772-9030
  • Sanz, Julián
  • González Larriba, José Luis|||0000-0003-2631-0309
  • Atienza-Cuevas, Lidia
  • Arriola-Arellano, Esperanza
  • Abdulkader, Ihab
  • Garcia-Gonzalez, Jorge
  • Camacho, Carmen
  • Rodríguez-Abreu, Delvys|||0000-0003-0506-1366
  • Teixidó, Cristina|||0000-0002-7226-6567
  • Reguart, Noemi|||0000-0001-8190-499X
  • Gonzalez-Piñeiro, Ana
  • Lázaro, Martín|||0000-0002-0657-4713
  • Lozano, María Dolores
  • Gurpide, Alfonso
  • Gómez-Román, Javier
  • Lopez-Brea, M.
  • Pijuan, Lara|||0000-0002-9978-6933
  • Salido, Marta|||0000-0001-9988-5977
  • Arriola, Edurne|||0000-0001-8960-7519
  • Company, Amparo
  • Insa, Amelia|||0000-0002-3438-6170
  • Esteban Rodríguez, Isabel|||0000-0003-1576-7215
  • Saiz, Mónica
  • Azkona, Eider
  • Álvarez, Ramiro|||0000-0002-8053-7232
  • Artal, Ángel
  • Plaza, María Luz
  • Aguiar de Sousa, Diana|||0000-0002-6702-7924
  • Enguita, Ana Belén
  • Benito, Amparo
  • Paz-Ares, Luis|||0000-0002-3327-3246
  • Garrido, Pilar|||0000-0002-5899-6125
  • Lopez-Rios, Fernando
Introduction: The ROS1 gene rearrangement has become an important biomarker in NSCLC. The College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology testing guidelines support the use of ROS1 immunohistochemistry (IHC) as a screening test, followed by confirmation with fluorescence in situ hybridization (FISH) or a molecular test in all positive results. We have evaluated a novel anti-ROS1 IHC antibody (SP384) in a large multicenter series to obtain real-world data. Methods: A total of 43 ROS1 FISH-positive and 193 ROS1 FISH-negative NSCLC samples were studied. All specimens were screened by using two antibodies (clone D4D6 from Cell Signaling Technology and clone SP384 from Ventana Medical Systems), and the different interpretation criteria were compared with break-apart FISH (Vysis). FISH-positive samples were also analyzed with next-generation sequencing (Oncomine Dx Target Test Panel, Thermo Fisher Scientific). Results: An H-score of 150 or higher or the presence of at least 70% of tumor cells with an intensity of staining of 2+ or higher by the SP384 clone was the optimal cutoff value (both with 93% sensitivity and 100% specificity). The D4D6 clone showed similar results, with an H-score of at least 100 (91% sensitivity and 100% specificity). ROS1 expression in normal lung was more frequent with use of the SP384 clone (p < 0.0001). The ezrin gene (EZR)-ROS1 variant was associated with membranous staining and an isolated green signal FISH pattern (p = 0.001 and p = 0.017, respectively). Conclusions: The new SP384 ROS1 IHC clone showed excellent sensitivity without compromising specificity, so it is another excellent analytical option for the proposed testing algorithm.